Advertisement

Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations

      To read this article in full you will need to make a payment

      References

        • Venkitaraman A.R.
        Cancer suppression by the chromosome custodians, BRCA1 and BRCA2.
        Science. 2014; 343: 1470-1475
        • Paluch-Shimon S.
        • Cardoso F.
        • Sessa C.
        • et al.
        Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
        Ann Oncol. 2016; 27: v103-v110
      1. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. v.3.2019 www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

        • Eeles R.
        • Goh C.
        • Castro E.
        • et al.
        The genetic epidemiology of prostate cancer and its clinical implications.
        Nat Rev Urol. 2014; 11: 18-31
        • Castro E.
        • Goh C.
        • Olmos D.
        • et al.
        Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
        J Clin Oncol. 2013; 31: 1748-1757
        • Castro E.
        • Goh C.
        • Leongamornlert D.
        • et al.
        Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer.
        Eur Urol. 2015; 68: 186-193
        • Tryggvadottir L.
        • Vidarsdottir L.
        • Thorgeirsson T.
        • et al.
        Prostate cancer progression and survival in BRCA2 mutation carriers.
        J Natl Cancer Inst. 2007; 99: 929-935
        • Bancroft E.K.
        • Page E.C.
        • Castro E.
        • et al.
        Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
        Eur Urol. 2014; 66: 489-499
        • Mikropoulos C.
        • Selkirk C.G.H.
        • Saya S.
        • et al.
        Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
        Br J Cancer. 2018; 118: 266-276
        • Margel D.
        • Benjaminov O.
        • Ozalvo R.
        • et al.
        Personalized prostate cancer screening among men with high risk genetic predisposition—study protocol for a prospective cohort study.
        BMC Cancer. 2014; 14: 528
        • Mano R.
        • Tamir S.
        • Kedar I.
        • et al.
        Malignant abnormalities in male BRCA mutation carriers: results from a prospectively screened cohort.
        JAMA Oncol. 2018; 4: 872-874
        • Margel D.
        • Sela S.
        • Tamir S.
        • et al.
        Multi-parametric prostate MRI as a screening test among male BRCA carriers.
        Eur Urol Suppl. 2019; 18e1539
        • Taylor R.A.
        • Fraser M.
        • Livingstone J.
        • et al.
        Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
        Nat Commun. 2017; 813671
        • Taylor R.A.
        • Fraser M.
        • Rebello R.J.
        • et al.
        The influence of BRCA2 mutation on localized prostate cancer.
        Nat Rev Urol. 2019; 16: 281-290
        • Carter H.B.
        • Helfand B.
        • Mamawala M.
        • et al.
        Germline mutations in ATM and BRCA1/2 are associated with grade reclassification in men on active surveillance for prostate cancer.
        Eur Urol. 2019; 75: 743-749
        • Halstuch D.
        • Sela S.
        • Ber Y.
        • et al.
        Active surveillance for low-risk prostate cancer among men with high risk genetic predisposition.
        Eur Urol Suppl. 2019; 18e1727
        • Pierce L.J.
        • Strawderman M.
        • Narod S.A.
        • et al.
        Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
        J Clin Oncol. 2000; 18: 3360-3369
        • Chiu Y.-T.
        • Liu J.
        • Tang K.
        • et al.
        Inactivation of ATM/ATR DNA damage checkpoint promotes androgen induced chromosomal instability in prostate epithelial cells.
        PLoS One. 2012; 7e51108
        • Alsop K.
        • Fereday S.
        • Meldrum C.
        • et al.
        BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
        J Clin Oncol. 2012; 30: 2654-2663
        • Mateo J.
        • Carreira S.
        • Sandhu S.
        • et al.
        DNA-repair defects and olaparib in metastatic prostate cancer.
        N Engl J Med. 2015; 373: 1697-1708